BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res 2021;27:78-86. [PMID: 32873572 DOI: 10.1158/1078-0432.CCR-20-2063] [Cited by in Crossref: 80] [Cited by in F6Publishing: 88] [Article Influence: 26.7] [Reference Citation Analysis]
Number Citing Articles
1 Tully KH, Berg S, Paciotti M, Janisch F, Reese SW, Noldus J, Shariat SF, Choueiri T, Müller G, McGregor B, Chang SL, Trinh QD, Mossanen M. The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. Clin Genitourin Cancer 2023;21:63-8. [PMID: 36517393 DOI: 10.1016/j.clgc.2022.11.015] [Reference Citation Analysis]
2 Tsuzuki T, Ohe C, Osawa T, Yasuda Y, Tanaka T, Anai S, Kimura G, Yamana K, Hatakeyama S, Yoshimoto T, Nakagawa Y, Fukuyama T, Matsubara N, Uemura H. Prognostic value of immune phenotype and PD-L1 status in recurrent or metastatic renal cell carcinoma: an exploratory analysis of the ARCHERY study. Pathology 2023;55:31-9. [PMID: 36241555 DOI: 10.1016/j.pathol.2022.07.013] [Reference Citation Analysis]
3 John A, Spain L, Hamid AA. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. Curr Oncol 2023;30:923-37. [PMID: 36661719 DOI: 10.3390/curroncol30010070] [Reference Citation Analysis]
4 Doppalapudi SK, Kaldany A, Lichtbroun B, Singer EA. The Role of Immunotherapy in Renal Cell Carcinoma. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_232-1] [Reference Citation Analysis]
5 Delcuratolo MD, Tucci M, Turco F, Di Stefano RF, Ungaro A, Audisio M, Samuelly A, Brusa F, Audisio A, Di Maio M, Scagliotti GV, Buttigliero C. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. Crit Rev Oncol Hematol 2023;181:103881. [PMID: 36427772 DOI: 10.1016/j.critrevonc.2022.103881] [Reference Citation Analysis]
6 Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. J Immunother Cancer 2022;10. [PMID: 36549781 DOI: 10.1136/jitc-2022-005445] [Reference Citation Analysis]
7 Ouzaid I, Rioux-Leclercq N, Khene ZE, Bensalah K, Kammerer-Jacquet SF. Can Molecular Classifications Help Tailor First-line Treatment of Metastatic Renal Cell Carcinoma? A Systematic Review of Available Models. Eur Urol Open Sci 2023;47:12-9. [PMID: 36573246 DOI: 10.1016/j.euros.2022.11.006] [Reference Citation Analysis]
8 Jahangir M, Yazdani O, Kahrizi MS, Soltanzadeh S, Javididashtbayaz H, Mivefroshan A, Ilkhani S, Esbati R. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell Int 2022;22:401. [PMID: 36510217 DOI: 10.1186/s12935-022-02816-3] [Reference Citation Analysis]
9 Peng T, Liu B, Lin S, Cao C, Wu P, Zhi W, Wei Y, Chu T, Gui L, Ding W. APOBEC3G expression correlates with unfavorable prognosis and immune infiltration in kidney renal clear cell carcinoma. Heliyon 2022;8:e12191. [PMID: 36568653 DOI: 10.1016/j.heliyon.2022.e12191] [Reference Citation Analysis]
10 Takagi T. Optimization of first‐line systemic therapy in patients with advanced clear cell renal cell carcinoma. Int J of Urology 2022. [DOI: 10.1111/iju.15103] [Reference Citation Analysis]
11 Yao C, Zhang T, Wu T, Brugarolas J. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. Clin Cancer Res 2022;28:5013-20. [PMID: 35819272 DOI: 10.1158/1078-0432.CCR-21-2372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 2022;113:109365. [DOI: 10.1016/j.intimp.2022.109365] [Reference Citation Analysis]
13 Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 2022. [DOI: 10.1038/s41585-022-00676-0] [Reference Citation Analysis]
14 Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report . World J Clin Cases 2022; 10(32): 11942-11948 [DOI: 10.12998/wjcc.v10.i32.11942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang N, Hakimi AA, Chen Y. XL-ing at Induction of Apoptosis in Kidney Cancer through Inhibition of BCL-XL. Clin Cancer Res 2022;28:4600-2. [PMID: 35984355 DOI: 10.1158/1078-0432.CCR-22-2104] [Reference Citation Analysis]
16 Bigot P, Barthelemy P, Boissier R, Khene Z, Pettenati C, Bernhard J, Correas J, Doumerc N, Gimel P, Ingels A, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Albiges L, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progrès en Urologie 2022;32:1195-1274. [DOI: 10.1016/j.purol.2022.07.146] [Reference Citation Analysis]
17 Parosanu A, Stanciu IM, Pirlog C, Orlov Slavu C, Cotan H, Iaciu C, Popa AM, Olaru M, Moldoveanu O, Catalin B, Nitipir C. Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. Cureus 2022. [DOI: 10.7759/cureus.30821] [Reference Citation Analysis]
18 Yuasa T. Editorial: Biomarkers in genitourinary cancers: Volume II. Front Oncol 2022;12:1048736. [DOI: 10.3389/fonc.2022.1048736] [Reference Citation Analysis]
19 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
20 Donskov F, Pinto CA, Predoiu R, Fox C, Georgsen JB, Skaarup K, Burcu M, Perini R, Steiniche T. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. Acta Oncologica. [DOI: 10.1080/0284186x.2022.2119100] [Reference Citation Analysis]
21 Tian X, Xiang B, Jin L, Mi T, Wang J, Zhanghuang C, Zhang Z, Chen M, Shi Q, Liu F, Lin T, Wei G. Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour. Front Immunol 2022;13:920666. [DOI: 10.3389/fimmu.2022.920666] [Reference Citation Analysis]
22 Lee CH, Kang M, Kwak C, Kim SH, Kim JK, Park JY, Seo SI, Seo IY, Suh J, Song W, Song C, Yuk HD, Lee S, Lee HH, Chung J, Jeong CW, Jo JK, Choi CI, Choo SH, Han JH, Hwang EC, Kim M, Kim C, Choi SH, Hong S. 2021 Consensus Statements on the Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma From the Korean Renal Cancer Study Group (KRoCS). Korean J Urol Oncol 2022;20:151-162. [DOI: 10.22465/kjuo.2022.20.3.151] [Reference Citation Analysis]
23 Hino C, Nishino K, Pham B, Jeon WJ, Nguyen M, Cao H. Nivolumab plus ipilimumab induced endocrinopathy and acute interstitial nephritis in metastatic sarcomatoid renal-cell carcinoma: A case report and review of literature. Front Immunol 2022;13:993622. [DOI: 10.3389/fimmu.2022.993622] [Reference Citation Analysis]
24 Kapur P, Rajaram S, Brugarolas J. The expanding role of BAP1 in clear cell renal cell carcinoma. Hum Pathol 2022:S0046-8177(22)00206-4. [PMID: 35932824 DOI: 10.1016/j.humpath.2022.07.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Xu W, Anwaier A, Liu W, Wei G, Su J, Tian X, Xia J, Qu Y, Zhao J, Zhang H, Ye D. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. Front Immunol 2022;13:953721. [DOI: 10.3389/fimmu.2022.953721] [Reference Citation Analysis]
27 Amin MB, McKenney JK, Martignoni G, Campbell SC, Pal S, Tickoo SK. Low grade oncocytic tumors of the kidney: a clinically relevant approach for the workup and accurate diagnosis. Mod Pathol 2022. [PMID: 35896615 DOI: 10.1038/s41379-022-01108-5] [Reference Citation Analysis]
28 Tiako Meyo M, Chen J, Goldwasser F, Hirsch L, Huillard O. A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma. Ther Clin Risk Manag 2022;18:683-98. [PMID: 35837579 DOI: 10.2147/TCRM.S263832] [Reference Citation Analysis]
29 Noel J, Jouinot A, Alexandre J, Ulmann G, Bretagne M, Castel-ajgal Z, De Percin S, Vaquin-villeminey C, Revel M, Peyromaure M, Boudou-rouquette P, Arrondeau J, Gataa I, Durand J, Goldwasser F, Huillard O. Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. Cancers 2022;14:3214. [DOI: 10.3390/cancers14133214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Lalani AA, Heng DYC, Basappa NS, Wood L, Iqbal N, Mcleod D, Soulières D, Kollmannsberger C. Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Ther Adv Med Oncol 2022;14:175883592211086. [DOI: 10.1177/17588359221108685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol 2022;:JCO2200868. [PMID: 35728020 DOI: 10.1200/JCO.22.00868] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
32 Whaley RD, Cheng L. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases. Am J Surg Pathol 2022. [PMID: 35687360 DOI: 10.1097/PAS.0000000000001926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00290-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
34 Navani V, Ernst M, Wells JC, Yuasa T, Takemura K, Donskov F, Basappa NS, Schmidt A, Pal SK, Meza L, Wood LA, Ernst DS, Szabados B, Powles T, McKay RR, Weickhardt A, Suarez C, Kapoor A, Lee JL, Choueiri TK, Heng DYC. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Netw Open 2022;5:e2216379. [PMID: 35687336 DOI: 10.1001/jamanetworkopen.2022.16379] [Reference Citation Analysis]
35 Xiang Z, Li J, Zhang Z, Cen C, Chen W, Jiang B, Meng Y, Wang Y, Berglund B, Zhai G, Wu J. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. Front Pharmacol 2022;13:883655. [DOI: 10.3389/fphar.2022.883655] [Reference Citation Analysis]
36 Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. J Med Case Rep 2022;16:193. [PMID: 35581611 DOI: 10.1186/s13256-022-03426-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara Ö, Klatte T, Kriegmair MC, Marchioni M, Mir MC, Ouzaïd I, Pavan N, Pecoraro A, Roussel E, de la Taille A. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35546184 DOI: 10.1038/s41585-022-00592-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
38 Fujiwara R, Kageyama S, Yuasa T. Developments in personalized therapy for metastatic renal cell carcinoma. Expert Review of Anticancer Therapy. [DOI: 10.1080/14737140.2022.2075347] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Borchiellini D, Maillet D. Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patient. Bulletin du Cancer 2022;109:2S4-2S18. [DOI: 10.1016/s0007-4551(22)00234-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Lombardi P, Filetti M, Falcone R, Di Bidino R, Iacovelli R, Ciccarese C, Bria E, Tortora G, Scambia G, Daniele G. New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis. Cancer Treatment Reviews 2022;106:102377. [DOI: 10.1016/j.ctrv.2022.102377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Najafi M, Jahanbakhshi A, Gomar M, Iotti C, Giaccherini L, Rezaie O, Cavallieri F, Deantonio L, Bardoscia L, Botti A, Sardaro A, Cozzi S, Ciammella P. State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis. Current Oncology 2022;29:2995-3012. [DOI: 10.3390/curroncol29050244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Zhou L, Fang H, Yin M, Long H, Weng G. Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. J Clin Lab Anal 2022;:e24409. [PMID: 35441741 DOI: 10.1002/jcla.24409] [Reference Citation Analysis]
43 Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol 2022;:JCO2102938. [PMID: 35442713 DOI: 10.1200/JCO.21.02938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
44 Yuasa T, Urasaki T, Oki R. Recent Advances in Medical Therapy for Urological Cancers. Front Oncol 2022;12:746922. [DOI: 10.3389/fonc.2022.746922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Vano Y, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard J, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun C, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-carpentier C, Zucman-rossi J, Fridman WH, Sautès-fridman C, Oudard S. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00128-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
46 Fatima S, Ma Y, Safrachi A, Haider S, Spring KJ, Vafaee F, Scott KF, Roberts TL, Becker TM, de Souza P. Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers 2022;14:1669. [DOI: 10.3390/cancers14071669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer 2022;10:e004316. [PMID: 35304405 DOI: 10.1136/jitc-2021-004316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
48 Alimohammadi A, Fajkovic H, Remzi M, Shariat S, Schmidinger M. Recent pharmacological approaches for the treatment of renal cell carcinoma. Expert Rev Clin Pharmacol 2022. [PMID: 35285369 DOI: 10.1080/17512433.2022.2053521] [Reference Citation Analysis]
49 Fontes-sousa M, Calvo E. First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102374] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 An J, Packiam VT, Chennamadhavuni A, Richards J, Jain J, Mott SL, Garje R. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:786307. [PMID: 35083144 DOI: 10.3389/fonc.2021.786307] [Reference Citation Analysis]
51 Bersanelli M, Casartelli C, Buti S, Porta C. Renal cell carcinoma and viral infections: A dangerous relationship? World J Nephrol 2022; 11(1): 1-12 [DOI: 10.5527/wjn.v11.i1.1] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Jeelan Basha N, Basavarajaiah SM, Shyamsunder K. Therapeutic potential of pyrrole and pyrrolidine analogs: an update. Mol Divers. [DOI: 10.1007/s11030-022-10387-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
53 Gu YQ, Shen WY, Yang QY, Chen ZF, Liang H. Ru(III) complexes with pyrazolopyrimidines as anticancer agents: bioactivities and the underlying mechanisms. Dalton Trans 2022;51:1333-43. [PMID: 34989734 DOI: 10.1039/d1dt02765d] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
54 Kim IH, Lee HJ. The Frontline Immunotherapy-Based Treatment of Advanced Clear Cell Renal Cell Carcinoma: Current Evidence and Clinical Perspective. Biomedicines 2022;10:251. [PMID: 35203461 DOI: 10.3390/biomedicines10020251] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
55 Rosellini M, Marchetti A, Tassinari E, Nuvola G, Rizzo A, Santoni M, Mollica V, Massari F. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development 2022;7:131-149. [DOI: 10.1080/23808993.2022.2156786] [Reference Citation Analysis]
56 Merseburger AS, Grünwald V. Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. Die Urologie 2022. [DOI: 10.1007/978-3-642-41168-7_60-2] [Reference Citation Analysis]
57 Karachaliou GS, Hirshman N, Zhang T. Immunotherapy. Urologic Oncology 2022. [DOI: 10.1007/978-3-030-89891-5_15] [Reference Citation Analysis]
58 Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol 2022;32:61-8. [PMID: 34720102 DOI: 10.1097/MOU.0000000000000940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
59 Neuzil K, Gessner K, Hedgepeth J, Wobker SE, Wallen EM, Morgan KP, Bjurlin MA, Rose TL. Complete pathologic response to pembrolizumab and axitinib in a patient with sarcomatoid RCC and ocrelizumab-treated multiple sclerosis. Urology 2021:S0090-4295(21)01186-9. [PMID: 34973243 DOI: 10.1016/j.urology.2021.12.015] [Reference Citation Analysis]
60 Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021;6:100304. [PMID: 34864348 DOI: 10.1016/j.esmoop.2021.100304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hahn AW, Shah AY, Campbell MT. First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. KCA 2021;5:207-17. [DOI: 10.3233/kca-210123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Candelario N, Geiger C, Flaig T. Sarcomatoid Renal Cell Carcinoma: The Present and Future of Treatment Paradigms. KCA 2021;5:167-79. [DOI: 10.3233/kca-210126] [Reference Citation Analysis]
63 Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Kuczyk MA. [Interdisciplinary recommendations for the treatment of advanced renal cell carcinoma]. Aktuelle Urol 2021. [PMID: 34852368 DOI: 10.1055/a-1579-0562] [Reference Citation Analysis]
64 Elias R, Tcheuyap VT, Kaushik AK, Singla N, Gao M, Reig Torras O, Christie A, Mulgaonkar A, Woolford L, Stevens C, Kettimuthu KP, Pavia-Jimenez A, Boroughs LK, Joyce A, Dakanali M, Notgrass H, Margulis V, Cadeddu JA, Pedrosa I, Williams NS, Sun X, DeBerardinis RJ, Öz OK, Zhong H, Seshagiri S, Modrusan Z, Cantarel BL, Kapur P, Brugarolas J. A renal cell carcinoma tumorgraft platform to advance precision medicine. Cell Rep 2021;37:110055. [PMID: 34818533 DOI: 10.1016/j.celrep.2021.110055] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
65 Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Maio MD. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy 2021. [PMID: 34806404 DOI: 10.2217/imt-2021-0157] [Reference Citation Analysis]
66 Nwabundo A, Damilola G, Olabisi AO, Ishmael J. Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma. J Kidney Cancer VHL 2021;8:38-42. [PMID: 34765405 DOI: 10.15586/jkcvhl.v8i4.168] [Reference Citation Analysis]
67 Yoshida T, Ohe C, Ikeda J, Atsumi N, Ohsugi H, Sugi M, Higasa K, Saito R, Tsuta K, Matsuda T, Kinoshita H. Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade. J Immunother Cancer 2021;9:e002922. [PMID: 34580162 DOI: 10.1136/jitc-2021-002922] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
68 Sejima T, Masago T, Yoshida M, Nishi T, Kawabata Y, Tajima Y, Yumioka T, Honda M, Takenaka A. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy. Int Cancer Conf J 2021;10:285-9. [PMID: 34567939 DOI: 10.1007/s13691-021-00501-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
69 Patel HV, Srivastava A, Srinivasan R, Singer EA. A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma. Curr Opin Oncol 2021;33:212-20. [PMID: 33818540 DOI: 10.1097/CCO.0000000000000721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Tito C, De Falco E, Rosa P, Iaiza A, Fazi F, Petrozza V, Calogero A. Circulating microRNAs from the Molecular Mechanisms to Clinical Biomarkers: A Focus on the Clear Cell Renal Cell Carcinoma. Genes (Basel) 2021;12:1154. [PMID: 34440329 DOI: 10.3390/genes12081154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
71 Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci 2021;22:6237. [PMID: 34207825 DOI: 10.3390/ijms22126237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treat Res Commun 2021;27:100349. [PMID: 33725559 DOI: 10.1016/j.ctarc.2021.100349] [Reference Citation Analysis]
73 Tomioka M, Nakane K, Ozawa K, Iinuma K, Suzui N, Miyazaki T, Koie T. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab. Cancer Rep (Hoboken) 2021;4:e1356. [PMID: 33656804 DOI: 10.1002/cnr2.1356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Adashek JJ, Zhang Y, Skelton WP 4th, Bilotta A, Chahoud J, Zemp L, Li J, Dhillon J, Manley B, Spiess PE. Dissecting Outcomes: Should Cytoreductive Nephrectomy Be Performed for Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation? Front Oncol 2020;10:627025. [PMID: 33643921 DOI: 10.3389/fonc.2020.627025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
75 Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021;12:808. [PMID: 33547292 DOI: 10.1038/s41467-021-21068-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
76 Donskov F. Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need. Ann Transl Med 2021;9:97. [PMID: 33569399 DOI: 10.21037/atm-20-7009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Serzan MT, Atkins MB. Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma. J Cancer Metastasis Treat 2021;7:39. [PMID: 35295921 DOI: 10.20517/2394-4722.2021.76] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
78 Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 2021;19:103-16. [PMID: 33358151 DOI: 10.1016/j.clgc.2020.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
79 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
80 Pichler R. Immune Checkpoint Inhibitors in Uro-Oncology: Urgent Call for Biomarkers. Cancers (Basel) 2020;12:E2768. [PMID: 32992444 DOI: 10.3390/cancers12102768] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
81 Tucker MD, Rini BI. Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2020;12:E2662. [PMID: 32961934 DOI: 10.3390/cancers12092662] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]